Success Story: Virology Expert Secures EB-1B Approval in Just 18 Days
Client’s Testimonial:
“Thank you so much for all your help throughout this process. I truly appreciate your guidance and support. I would be happy to recommend your services to my friends.”
On September 8th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Research Scientist in the Field of Virology (Approval Notice).
General Field: Virology
Position at the Time of Case Filing: Research Scientist
Country of Origin: India
State of Residence at the Time of Filing: New York
Approval Notice Date: September 8th, 2026
Processing Time: 18 days (Premium Processing Requested)
Case Summary:
Research in virology addresses some of the world's most critical public health challenges, from deciphering fundamental viral replication mechanisms to engineering novel antiviral therapies capable of preventing severe disease outbreaks. This imperative defined the work of a virology expert whose I-140 petition sought classification as an EB-1B Outstanding Researcher. The client holds a Ph.D. in biotechnology and currently works as a research scientist at a major U.S. medical research institution.
Demonstrating Original Contributions Across Research Areas
The client has developed innovative therapeutic strategies, including engineered receptor-decoy constructs to neutralize viral entry, small-molecule approaches targeting viral replication complexes, and characterizations of host restriction factors that suppress viral synthesis.
To demonstrate the field-wide significance of these contributions, the petition highlighted how independent researchers and international research groups have actively relied upon and implemented the client's findings. Scientists across the globe have utilized the client's mechanistic frameworks and experimental models to benchmark new therapeutic candidates, design broad-spectrum antiviral agents, and explore host innate immune defenses. The client's research has also received major funding support from premier federal and private institutions, further contextualizing the scientific importance of the client's work.
Building the Record of International Recognition
The client's scholarly and professional record provided robust evidence of international acclaim required under the EB-1B standard. The client has authored 7 peer-reviewed journal articles (3 first-authored and 1 co-first-authored) and 1 book chapter, with research featured in highly selective, top-tier international journals. Furthermore, the client had completed at least 12 peer reviews for authoritative scientific journals. We presented these metrics not as standalone numbers, but alongside evidence showing how adjudicators evaluate citation volume, premier journal placement, and expert review requests as objective proof of sustained international scholarly reliance.
Expert Support for the Client's Standing
The petition included 4 recommendation letters from experts familiar with the client's standing in virology, including 3 independent advisory opinions from prominent scientists who knew the client's work strictly through the published record. These letters explained why the client's scientific breakthroughs mattered to the broader field and corroborated independent evidence of research influence, technical innovation, and ongoing scientific contributions.
EB-1B Approval in Just 18 Days
Filing with Direct Premium Processing requested from the outset, the client's I-140 EB-1B petition was approved in just 18 days without any Request for Evidence. By systematically bringing together evidence of original scientific contributions, high-impact scholarly authorship, international citation reliance, peer review activity, major funding support, expert testimony, and a qualifying permanent research position, we demonstrated a record fully consistent with international recognition as an outstanding researcher in virology.
We congratulate the client on this rapid EB-1B approval and wish her continued success in advancing research with vital applications in global health and infectious disease therapeutics.